Retatrutide is a new pharmaceutical in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, shows promising results in investigations. By activating these receptors, Retatrutide suppresses appetite, {promotesinsulin secretion, and ultimately results in si